USFDA accepts to review SPARC’s NDA for Taclantis

01 Jul 2019 Evaluate

The US Food and Drug Administration (USFDA) has accepted for review Sun Pharma Advanced Research Company’s (SPARC) New Drug Application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension). The NDA filing is based on successful demonstration of clinical bioequivalence of Taclantis with Abraxane and associated clinical safety data. SPARC seeks the same indications as Abraxane for Taclantis in the NDA. The USFDA confirmed that this NDA will be a standard review.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

134.45 0.00 (0.00%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 650.90
Indegene 520.55
CMS Info Systems 339.50
Sagility 52.02
Smartworks Coworking 496.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×